332 results about "Silibinin" patented technology

The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.

Personal care composition comprising at least one hair growth regulating compound selected from the group consisting of glyceryl dilaurate, apigenin, tetrahydrocurcumin, oleanolic acid, azelaic acid, sulforaphane, canavanine, pyridoxal 5-phosphate, phytic acid, tannic acid, grape seed extract, NG-nitro-L-arginine-methyl ester, benzamidine, sodium butyrate, betulinic acid, polyornithine, polyarginine, fisetin, jasmonates, methyl-jasmonate, cis-jasmone, caffeic acid phenethyl ester, delphinidin, ethyl abietate, esculetin, sorbic acid methyl ester, canaline, N-formyl-methionine, N-formyl-alanine, taurine, palmitoyl carnitine, undecanol, undecylenic acid, rutin, fusidic acid, phenyl pyruvic acid, L-isoleucine, phenyl glycine, silibinin, silymarin, L-ascorbic acid-6-palmitate, N-undecylenoyl-L-phenylalanine, and salts, derivatives and mixtures of any of the foregoing; and a dermatologically-acceptable carrier.

The invention provides a composition with auxiliary protection effect on chemical hepatic injury and alcoholic hepatic injury and health care food thereof. The composition or the health care food comprises the following components in percentage by weight: 8-15% of silymarin, 10-20% of wolfberry fruit extract, 15-30% of licorice root extract, 15-20% of kudzuvine root extract, 15-20% of wolfberry fruit extract, and 12-25% of turmeric extract. The health care food provided by the invention has the comprehensive functions of silymarin, wolfberry fruit extract, licorice root extract, kudzuvine root extract, wolfberry fruit extract and turmeric extract, and the components take synergistic action, so as to greatly improve the administration effect of a single component. Functional tests prove that the health care food has auxiliary protection effect on chemical hepatic injury and alcoholic hepatic injury. The preparation method of the health care food is simple, which meets the need of large-scale industrial production.

The invention relates to application of diamine formyl dehydrogenated silybin serving as a medicament for curing viral hepatitis B, in particular to application of a flavonolignan of dehydrogenated silibinin esters of which the ring A and the ring E have diamine formyl-methoxyl substituents or pharmaceutically acceptable salts thereof in preparation of a medicament for clearing HBsAg and HBeAg and a medicament for inhibiting HBV DNA replication. The flavonolignan of dehydrogenated silibinin esters of which the ring A and the ring E have diamine formyl-methoxyl substituents has extremely high HBsAg and HBeAg inhibiting activities; when the flavonolignan of dehydrogenated silibinin esters of which the ring A and the ring E have diamine formyl-methoxyl substituents is at a concentration of 20 mu g/ml, the inhibition rates of the HBsAg and the HBeAg are respectively 94.4 percent and 95.7 percent which exceed 5.9 times and 5.7 times those of a positive control alpha-interferon; and simultaneously the inhibition rate of the HBV DNA is 99.7 percent when the flavonolignan of dehydrogenated silibinin esters of which the ring A and the ring E have diamine formyl-methoxyl substituents is at the same concentration, and the inhibition activity of the flavonolignan of dehydrogenated silibinin esters of which the ring A and the ring E have diamine formyl-methoxyl substituents is higher than that of lamivudine and the alpha-interferon. In summary, the flavonolignan of dehydrogenated silibinin esters of which the ring A and the ring E have diamine formyl-methoxyl substituents or the pharmaceutically acceptable salts thereof can be expected for preparing non-nucleoside medicaments for clearing the HBsAg and the HBeAg, inhibiting the HBV DNA replication, and curing the hepatitis B virus infection diseases.

The invention relates to application of aromatic carbamoyl dehydro-silibinin as a medicament for treating viral hepatitis B, in particular to application of todehydro-silibinin flavonolignans with a ring A and a ring E which are substituted by double base aromatic carbamoyl methoxyl and pharmaceutically acceptable salt thereof for preparing medicaments for removing HBsAg and HBeAg and medicaments for inhibiting HBV DNA. The todehydro-silibinin flavonolignans has extremely obvious activity on inhibiting the HBsAG and the HBeAg, has the intensity of 46.2 percent and 68.9 percent for respectively removing the HBsAG and the HBeAg in the presence of the concentration of 100 microgram/milliliter, which is 2.9 times and 4.1 times higher than that of positive control medicament alpha-interferon, and has the inhibition ratio of 96 percent on HBV DNA in the presence of the concentration of 100 microgram/milliliter, which is higher than that of lamivudine and the alpha-interferon. Accordingly, the flavonolignans and the pharmaceutically acceptable salt thereof can be expected to be used for preparing non-nucleoside medicaments applied for removing HBsAg and HBeAg, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases.

The invention relates to application of E-ring demethoxy-silibinin for preparing medicaments for treating viral hepatitis B, and particularly to application of compound in formula (1) and pharmaceutically acceptable salt thereof for preparing medicaments for clearing HBsAg and HBeAg and suppressing HBV DNA replication. The invention has extremely superactive activity for suppressing the HBsAg and HBeAg; in the presence of the concentration of 20 microgram per millilitre, the intensities for clearing the HBsAg and HBeAg are 95.0% and 34.4% respectively, which are 5.9 and 2.0 times corresponding activity of a positive control medicament alpha-interferon; and it should be noticed that the suppression ratio of the medicament for HBV DNA at the concentration is about 91.5%, which is 13% higher than lamivudine and 2.4 times alpha-interferon suppression activity. In summary, the flavonolignans or pharmaceutically acceptable salt thereof can be prospectively used for preparing non-nucleoside medicaments for clearing the HBsAg and HBeAg, suppressing HBV DNA replication and treating hepatitis B virus infection disease.

The invention provides a production method of silymarin, which comprises the following steps: shelling silybum marianum seeds; filling the silybum marianum shells into a softening tank, and softening the silybum marianum shells with vapor; filling the softened silybum marianum shells into a flat-turn extractor, and adding ethanol to carry out extraction, thereby obtaining an extracting solution; concentrating the extracting solution to a certain degree to obtain a concentrated solution; adding aqueous alkali into the concentrated solution, stirring and standing to precipitate; and filtering the precipitate, drying, pulverizing and screening. In the extraction process, no toxic or harmful reagent is adopted, and no solvent residue which is harmful to the product can be produced; the ultraviolet detection indicates that the total flavone content in the product can be higher than 70%, the contents of silybin and isosilybin can be higher than 30%, and the product yield is 3-4% of the silybum marianum seeds; and therefore, the invention has the advantages of high extraction efficiency, simple technique and low solvent consumption.

The invention relates to a novel process for the isolation of a hepatoprotective agent Silymarin from the seeds of the plant Silybum marianum comprising (i) Precooling the seeds to (-) 20° C. for 24 hours in a deep freezer/cold room. (ii) Powdering the cooled seeds in a hammer mill, fitted with about 40 mesh discharge screen. (iii) Defatting the seeds by extracting with hexane in a soxhlet type extractor to remove the total quantity of fatty oil without using a scrain. (iv) Extracting the defatted seeds with acetonitrile at 20-30° C. to extract silymarin fraction. (v) Concentration of the sensitive silymarin fraction under vacuum in a agitated wiped thin film evaporator (vi) stirring the silymarin such dry powder with cold dichloromethane at 5° C. followed by filtration and drying with a slow purge of nitrogen gas. (vii) Further purification of silymarin by suspending in 5 times its weight of acetonitrile and precipitating by 8-12 times its weight of water at 20° C. (viii) Filtering the precipitated silymarin in a closed vacuum filter and having 1-2 mum screen washing the cake three times with distilled water (ix) Drying of Silymarin cake in vacuum oven to obtain substantially pure silymarin.

A freeze-dried powder injection of silibinin salt features that it contains silibinin salt which may be the inorganic or organic alkaline salt of silibinin or its salt of amino acid, the pH regulator and/or solubilizer.

The present invention features that silybin is included by cyclodextrin or its derivative so as to dissolve in water to prepare injection. The present invention solves the problem of water insoluble silybin for being suitable for intravenous injection.

An oral micro-emulsion composition comprising a Carduus marianus extract, silybin or a silybin derivative; an organic solvent; a surfactant; and an oil provides a high in vivo bioavailability of silybin.

The invention relates to a silibinin flavonolignan and its medicine salt or solvates. The invention also relates to the method preparing its important mediate and its drug combination and medical application. The compound can protect primary hepatocyte from oxidative damage for SD newly born rat hepatitis virus, so it is expected to be used as drug preventing liver damage. The compound can remove superoxide anion free radical and diphenyl picryl phenylhydrazine free radical, inhibit free radical from inducing generation of fat oxidatant, protect PC 12 cell from being damaged by free radical, so it is expected to be used as drug treating diseases caused by free radical.

The invention discloses a production method for simultaneously extracting silybum marianum oil and silymarin from a silybum marianum cake. The method comprises the following steps: (a) performing multistage pulse counter-current extraction on the silybum marianum cake to obtain a mixed solution containing the silybum marianum oil and the silymarin, wherein the solvent used in the extracting process is a mixed solvent of the methanol and the normal hexane at a mass ratio of (0.6-1):1; (b) filtering and separating the mixed solution containing the silybum marianum oil and the silymarin to obtain the silybum marianum oil normal hexane mixed solution and the silymarin methanol mixed solution; (c) performing negative-pressure counter-current film evaporation and negative-pressure water vapor steam distillation on the silybum marianum oil normal hexane mixed solution to obtain the silybum marianum oil; and (d) performing negative-pressure climbing film evaporation, negative-pressure rectification and spray dehydration on the silymarin methanol mixed solution to obtain the silymarin. By adopting the method provided by the invention, the extracting rate of the silymarin is greatly increased and the problems of large input of the solvent and low extracting rate in the silymarin production process can be solved; the production process is free of pollution and low in cost, so that the large-scale, industrial and continuous production of the silymarin can be realized.

The invention relates to a method for preparing Silymarin. The method has the advantages that the operation is simple and convenient, the pollution is low and the equipment investment is small. The technological steps are that: Silybum marianum fine powder is taken and is added in a CO2 supercritical extractor, methanol is used as entrainer, the entrainer accounts for 2-6 percent of the total volume of extraction solvent, the extraction pressure is 10-40MPa, the extraction temperature is 30-60 DEG C, CO2 flow is 1-5ml per gram crude drug per minutes, the extraction time is 150-250min, the extract is obtained, acetone is added, agitation is conducted to enable the acetone to be dissolved, filtration is conducted, the filtered liquid is obtained and is concentrated, the obtain liquid is filled in a high-efficiency countercurrent extractor, water-acetone-chloroform (1:5:2) solvent system is used, the bottom phase is a fixed phase, the top phase is a flowing phase, Silymarin segments are collected and are concentrated, crystals are precipitated and are separated, and acetone-petroleum ether (0.5-2:1) are added for recrystallization. The invention has the advantages that the purity of the prepared Silymarin is high and the industrialization amplification can be realized easily.

The invention discloses water-soluble silymarin, which is an inclusion compound that takes cyclodextrin as main molecules and silymarin as guest molecules; and the inclusion compound contains 12 to 20wt % of silybinin. The preparation method thereof comprises the following steps: silybum marianum seeds are squeezed into silybum marianum cakes; the silybum marianum cakes are added into alkali water ethanol solution and are heated to 75DEG C to 85DEG C, the constant temperature is kept for 1.5-2.5 hours, and silybum marianum extracting solution is prepared after 2-4 times of continuous extraction; the silybum marianum extracting solution is added with the cyclodextrin for inclusion, thus obtaining inclusion compound solution; flocculant is added, standing after being well stirred; after flocculate is filtered out, membrane separation process is carried out, thus obtaining water-soluble silymarin solution; and after the membrane separation process, the water-soluble silymarin solution is concentrated and dried, thus obtaining the dried product of the water-soluble silymarin. The water-soluble silymarin prepared by the method has the advantages of high solubility, good quality, good drug stability and high bioavailability.

Described is a composition for the prevention and treatment of symptoms associated with ethyl alcohol consumption. The composition comprises silymarin, salicin, at least one B vitamin, magnesium, molybdenum and manganese. Treatment of symptoms associated with the consumption of ethyl alcohol involves ingesting the described composition prior to, during, or after the consumption of the alcohol.

The invention discloses epidermal growth factor compound lipidosome as well as a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The epidermal growth factor compound lipidosome is prepared by the following raw materials in parts by mass: 0.1-5 parts of epidermal growth factors, 5-30 parts of silibinin, 5-30 parts of coix seed oil, 5-30 parts of yeast extracts, 5-30 parts of microbial polysaccharide, 30-200 parts of hydrogenated lecithin, 10-80 parts of cholesterol and 5-30 parts of glycerinum. The epidermal growth factor compound lipidosome has the advantages of simple technique, safety, no poison, little skin irritation, mild property and stable effect.

The invention relates to a silybin injection and its preparation method, which comprises silybin meglumine, glucosamine, alkaline amino acid solubiliser and pharmaceutically acceptable solvent, or compound of silybin and alkaline solubiliser and pharmaceutically acceptable solvent, the pH is 4-11. The injection also comprises one or more of pharmaceutically acceptable solubilizer, pH regulator, isotonic conditioning agent, painkiller, anti-oxidant agent, preservative and complexing agent.

The invention provides a method for extracting silymarin from milk thistle seed coat. The objective of the invention is to solve the following problem in the prior art: the extraction of silymarin from milk thistle exotesta uses the integral body of milk thistle as the raw material, and therefore the extracted coarse silymarin contains considerable impurities and has to be refined; the process of refinement is cumbersome and consumes considerable organic solvents. The method provided in the invention comprises the following steps: cleaning milk thistle seeds; decorticating the milk thistle seeds with a decorticator so as to obtain milk thistle seed coats and seed kernels respectively; carrying out extraction on the milk thistle seed coats with a solvent; recovering the solvent by condensation so as to obtain silymarin. According to the invention, silymarin extracted from milk thistle seed coats has a quality far surpassing the international standard.